112 related articles for article (PubMed ID: 17316479)
1. [Assessment of the economic impact of the antiretroviral vaccine in Venezuela].
Constenla D; Pérez-Schael I; Rheingans RD; Antil L; Salas H; Yarzábal JP
Rev Panam Salud Publica; 2006 Oct; 20(4):213-22. PubMed ID: 17316479
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a new rotavirus vaccination program in Pakistan: a decision tree model.
Patel HD; Roberts ET; Constenla DO
Vaccine; 2013 Dec; 31(51):6072-8. PubMed ID: 24176497
[TBL] [Abstract][Full Text] [Related]
3. [Potential cost effectiveness of a rotavirus vaccine in Chile].
Constenla D; O'Ryan M; Navarrete MS; Antil L; Rheingans RD
Rev Med Chil; 2006 Jun; 134(6):679-88. PubMed ID: 17130941
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of rotavirus vaccination in Kenya and Uganda.
Sigei C; Odaga J; Mvundura M; Madrid Y; Clark AD; ;
Vaccine; 2015 May; 33 Suppl 1():A109-18. PubMed ID: 25919149
[TBL] [Abstract][Full Text] [Related]
5. Economic impact of a rotavirus vaccination program in Mexico.
Constenla D; Velázquez FR; Rheingans RD; Antil L; Cervantes Y
Rev Panam Salud Publica; 2009 Jun; 25(6):481-90. PubMed ID: 19695142
[TBL] [Abstract][Full Text] [Related]
6. Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries.
Rheingans RD; Constenla D; Antil L; Innis BL; Breuer T
Rev Panam Salud Publica; 2007 Apr; 21(4):205-16. PubMed ID: 17612464
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis for evidence-based policy-making on a national immunization program: a case of rotavirus vaccine in Thailand.
Muangchana C; Riewpaiboon A; Jiamsiri S; Thamapornpilas P; Warinsatian P
Vaccine; 2012 Apr; 30(18):2839-47. PubMed ID: 22387220
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of rotavirus vaccination in Argentina.
Urueña A; Pippo T; Betelu MS; Virgilio F; Hernández L; Giglio N; Gentile Á; Diosque M; Vizzotti C
Vaccine; 2015 May; 33 Suppl 1():A126-34. PubMed ID: 25919152
[TBL] [Abstract][Full Text] [Related]
9. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule.
Milne RJ; Grimwood K
Value Health; 2009 Sep; 12(6):888-98. PubMed ID: 19490550
[TBL] [Abstract][Full Text] [Related]
10. Economic impact of a rotavirus vaccine in Brazil.
Constenla DO; Linhares AC; Rheingans RD; Antil LR; Waldman EA; da Silva LJ
J Health Popul Nutr; 2008 Dec; 26(4):388-96. PubMed ID: 19069617
[TBL] [Abstract][Full Text] [Related]
11. [Economic impact of rotavirus vaccination in Panama].
Constenla D; Ortega-Barría E; Rheingans RD; Antil L; Sáez-Llorens X
An Pediatr (Barc); 2008 Feb; 68(2):128-35. PubMed ID: 18341878
[TBL] [Abstract][Full Text] [Related]
12. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of rotavirus vaccination in Albania.
Ahmeti A; Preza I; Simaku A; Nelaj E; Clark AD; Felix Garcia AG; Lara C; Hoestlandt C; Blau J; Bino S
Vaccine; 2015 May; 33 Suppl 1():A201-8. PubMed ID: 25919162
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of rotavirus vaccination programs in Taiwan.
Chang WC; Yen C; Chi CL; Wu FT; Huang YC; Lin JS; Huang FC; Tate JE; Wu HS; Hsiung CA
Vaccine; 2013 Nov; 31(46):5458-65. PubMed ID: 24060569
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
Abbott C; Tiede B; Armah G; Mahmoud A
Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
[TBL] [Abstract][Full Text] [Related]
16. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of rotavirus vaccination in Turkey.
Koksal T; Akelma AZ; Koksal AO; Kutukoglu I; Ozdemir O; Yuksel CN; Bozkaya D; Catal F; Sari S
J Microbiol Immunol Infect; 2017 Oct; 50(5):693-699. PubMed ID: 27107612
[TBL] [Abstract][Full Text] [Related]
18. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
19. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
[TBL] [Abstract][Full Text] [Related]
20. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
